Oculis Holding

Filter

År

Typ

Språk

Rensa

2026-09-17 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 1235,00 ISK | +2,92% | 33,6 MISK

2026-08-24 10:00:00 First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis 1570,00 ISK | -1,72% | 9,80 MISK

2026-08-24 10:00:00 Fyrsti sjúklingurinn fær meðferð í PIONEER-1 skráningarrannsókninni á Privosegtor við sjóntaugabólgu 1570,00 ISK | -1,72% | 9,80 MISK

2026-08-24 10:00:00 First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis 1570,00 ISK | -1,72% | 9,80 MISK

2026-08-14 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-08-10 09:30:00 Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company 1550,00 ISK | -0,64% | 24,9 MISK

2026-08-10 09:01:50 Oculis undirritar kaupsamning við Accure Therapeutics um leiðandi þróunarlyfið Privosegtor og eflir þannig stöðu Oculis sem leiðandi vaxtarfyrirtækis á sviði taugaaugnlækninga 1550,00 ISK | -0,64% | 24,9 MISK

2026-08-10 09:01:50 Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company 1550,00 ISK | -0,64% | 24,9 MISK

2026-08-06 22:05:00 Oculis Reports Q2 2026 Financial Results and Provides Company Update 1560,00 ISK | +4,00% | 16,5 MISK

2026-08-06 22:05:00 Oculis birtir uppgjör fyrir annan ársfjórðung 2026 og kynnir áfanga í rekstri félagsins 1560,00 ISK | +4,00% | 16,5 MISK

2026-08-06 22:05:00 Oculis Reports Q2 2026 Financial Results and Provides Company Update 1560,00 ISK | +4,00% | 16,5 MISK

2026-08-03 10:00:00 Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

2026-07-08 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 1760,00 ISK | +4,45% | 27,6 MISK

2026-07-02 10:00:00 Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference 1765,00 ISK | +2,62% | 26,8 MISK

2026-06-15 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 1405,00 ISK | +0,36% | 9,96 MISK

2026-06-11 10:00:00 Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 1372,50 ISK | -1,96% | 31,5 MISK

2026-06-10 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 1372,50 ISK | -1,96% | 31,5 MISK

2026-06-09 21:21:06 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 1400,00 ISK | 0,00% | 13,3 MISK

2026-06-09 10:00:00 Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease 1400,00 ISK | +7,69% | 46,1 MISK

2026-06-08 21:25:37 Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference 1400,00 ISK | +7,69% | 46,1 MISK

2026-06-08 20:45:31 Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference 1400,00 ISK | +7,69% | 46,1 MISK

2026-05-29 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-05-29 21:54:00 Íslensk þýðing á fyrri tilkynningu; Oculis tilkynnir um helstu niðurstöður úr fasa 3 DIAMOND rannsóknunum á OCS-01 við sjónhimnubjúg af völdum sykursýki

2026-05-29 21:06:05 Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

2026-05-29 20:52:47 Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

2026-05-28 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 3650,00 ISK | -0,27% | 62,9 MISK

2026-05-15 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-05-14 22:05:00 Oculis birtir niðurstöður aðalfundar 2026 og tilkynnir um kjör Gregory D. Perry í stjórn félagsins 3680,00 ISK | -0,81% | 12,6 MISK

2026-05-14 22:05:00 Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors 3680,00 ISK | -0,81% | 12,6 MISK

2026-05-11 22:07:00 Oculis Reports Q1 2026 Financial Results and Provides Company Update 3820,00 ISK | -6,83% | 184 MISK

2026-05-07 11:00:00 Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial 3820,00 ISK | +9,14% | 502 MISK

2026-05-07 10:57:37 Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial 3820,00 ISK | +9,14% | 502 MISK

2026-05-05 10:00:00 Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting 3520,00 ISK | +2,03% | 349 MISK

2026-05-01 10:00:00 Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

2026-04-21 22:05:00 Oculis birtir boð á aðalfund 3420,00 ISK | +0,29% | 71,4 MISK

2026-04-21 22:05:00 Oculis Publishes Invitation to the Annual General Meeting 3420,00 ISK | +0,29% | 71,4 MISK

2026-04-20 10:00:00 Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema 3520,00 ISK | +5,71% | 454 MISK

2026-04-20 10:00:00 Oculis lýkur síðustu eftirfylgniheimsókn í fasa 3 DIAMOND rannsóknaráætluninni með OCS-01 augndropum til meðferðar á sjónhimnubjúg af völdum sykursýki 3520,00 ISK | +5,71% | 454 MISK

2026-04-20 10:00:00 Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema 3520,00 ISK | +5,71% | 454 MISK

2026-04-08 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 3370,00 ISK | 0,00% | 0,63 MISK

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode